Soltis Investment Advisors LLC Invests $242,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Soltis Investment Advisors LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,616 shares of the biopharmaceutical company’s stock, valued at approximately $242,000.

Other institutional investors have also recently bought and sold shares of the company. Bellevue Group AG lifted its holdings in shares of Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after buying an additional 7,093 shares during the last quarter. Quantinno Capital Management LP raised its position in Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC grew its position in Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after acquiring an additional 3,627 shares in the last quarter. IRON Financial LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth $830,000. Finally, Capital Investment Advisors LLC raised its holdings in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after purchasing an additional 9,791 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 572,824 shares of company stock valued at $53,611,715. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of a number of recent research reports. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Bank of America reiterated a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research note on Tuesday, December 10th. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Truist Financial upped their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Finally, Morgan Stanley upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $87.00 to $113.00 in a report on Friday, January 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Price Performance

Shares of GILD stock opened at $96.14 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $100.51. The company has a market capitalization of $119.82 billion, a P/E ratio of 1,068.22, a P/E/G ratio of 1.25 and a beta of 0.18. The stock has a 50 day moving average of $93.07 and a two-hundred day moving average of $86.99. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.